Attovia Therapeutics Inc. Common Stock (ATTO)
Stock · NASDAQ · Health Care
$13.74as of 10/16/2026
Price chart
Active signals
High Beta100.0%
Industry
Biotechnology: Biological Products (No Diagnostic Substances)
About ATTO
Attovia Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops biotherapeutics for immune-mediated diseases in the United States. The company provides ATTOBODY, a biparatopic biologics platform designed to deliver improved treatments. The company's products include ATTO-1310, a novel ATTOBODY-based Fc-fusion protein therapeutic that inhibits IL-31; developed for the treatment of chronic pruritic dis…
- Sector
- Health Care
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- Employees
- 44
- Website
- www.attovia.com
Fundamentals
- 1-day range
- $12.98$15.17
- Market cap
- $928.90M
- P/E (trailing)
- 0.00
- P/E (forward)
- -5.77
- EPS (trailing)
- $-13.88
- Dividend yield
- —
- Beta
- 15442.25
- Avg. volume
- 459.1K
52-week range
$14.23$28
Next earnings: November 11, 2026 · EPS estimate $-0.50
Attovia Therapeutics Inc. Common Stock Competitors
Chosen by industry and closest market cap.
- ATTOAttovia Therapeutics Inc. Common Stock$13.73▼ 7.10%Market cap $928.90MP/E 0.00$14.23$28
- SANASana Biotechnology Inc. Common Stock$2.27▼ 8.28%Market cap $948.97MP/E —$2.32$6.55
- SLDBSolid Biosciences Inc. Common Stock$5.53▼ 3.66%Market cap $857.50MP/E —$3.79$11.45
- ODTXOdyssey Therapeutics Inc. Common Stock$17.17▼ 2.28%Market cap $1.04BP/E —$15.1$29.05
- DBVTDBV Technologies S.A. American Depositary Shares$9.05▼ 0.66%Market cap $813.58MP/E —$1.57$4.5
- AURAAura Biosciences Inc. Common Stock$6.1▼ 3.79%Market cap $798.53MP/E —$4.73$9.54
- REPLReplimune Group Inc. Common Stock$10.86▼ 7.57%Market cap $1.08BP/E —$1.5$16.33
| Symbol | Market cap | P/E ratio | Price | 1D | 52-week range |
|---|---|---|---|---|---|
| ATTO Attovia Therapeutics Inc. Common Stock | $928.90M | 0.00 | $13.73 | ▼ 7.10% | $14.23$28 |
| SANA Sana Biotechnology Inc. Common Stock | $948.97M | — | $2.27 | ▼ 8.28% | $2.32$6.55 |
| SLDB Solid Biosciences Inc. Common Stock | $857.50M | — | $5.53 | ▼ 3.66% | $3.79$11.45 |
| ODTX Odyssey Therapeutics Inc. Common Stock | $1.04B | — | $17.17 | ▼ 2.28% | $15.1$29.05 |
| DBVT DBV Technologies S.A. American Depositary Shares | $813.58M | — | $9.05 | ▼ 0.66% | $1.57$4.5 |
| AURA Aura Biosciences Inc. Common Stock | $798.53M | — | $6.1 | ▼ 3.79% | $4.73$9.54 |
| REPL Replimune Group Inc. Common Stock | $1.08B | — | $10.86 | ▼ 7.57% | $1.5$16.33 |
P/E shows — for peers not currently carrying a live signal of their own.
Latest news
- Attovia Therapeutics To Present New Clinical, Translational, And Preclinical Data Across Its Pipeline At EADV Congress And FCD 2026benzinga · 9/28/2026
- Attovia Therapeutics to Present New Data on ATTO-1310 and ATTO-2306 at EADV 2026 and Fall Clinical Dermatology Conference 2026Yahoo · 9/28/2026
- Attovia Therapeutics To Present New Clinical, Translational, And Preclinical Data Across Its Pipeline At EADV Congress And FCD 2026Benzinga · 9/28/2026
- Was Moderna Stock's Cancer Vaccine Run Visible In Advance?Yahoo · 9/22/2026
- Attovia Therapeutics (ATTO) Pulls Back As Investors Ask If The Valuation Still FitsYahoo · 9/22/2026
- Attovia Therapeutics, Inc. (ATTO) Presents at Morgan Stanley 24th Annual Global Healthcare Conference TranscriptSeekingAlpha · 9/16/2026
Insider Activity
Insider Actions →Acquired
5.78M
Disposed
80.55M
- WALSH COLIN · August 6, 2026 · Conversion4.45M
- WALSH COLIN · August 6, 2026 · Conversion18.18M
- WALSH COLIN · August 6, 2026 · Buy500.0K @ $17
- WALSH COLIN · August 6, 2026 · Conversion478.5K
- WALSH COLIN · August 6, 2026 · Conversion1.96M
- GOLDMAN SACHS GROUP INC · August 6, 2026 · Conversion4.45M
- GOLDMAN SACHS GROUP INC · August 6, 2026 · Conversion18.18M
- GOLDMAN SACHS GROUP INC · August 6, 2026 · Buy500.0K @ $17
- GOLDMAN SACHS GROUP INC · August 6, 2026 · Conversion478.5K
- venBio Global Strategic Fund IV, L.P. · August 6, 2026 · Conversion6.18M
- venBio Global Strategic Fund IV, L.P. · August 6, 2026 · Conversion7.64M
- venBio Global Strategic Fund IV, L.P. · August 6, 2026 · Conversion21.48M
- venBio Global Strategic Fund IV, L.P. · August 6, 2026 · Buy382.4K @ $17
- venBio Global Strategic Fund IV, L.P. · August 6, 2026 · Conversion665.1K
- venBio Global Strategic Fund IV, L.P. · August 6, 2026 · Conversion822.0K
See the full, filterable feed with live charts on the MarketWall dashboard.
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 25, 2026
ATTO shares dip as investors question valuation after cancer vaccine news
Attovia Therapeutics' stock moved lower as investors raised concerns about whether its current valuation is justified. The scrutiny comes as the broader oncology space sees attention, highlighted by recent discussion of Moderna's cancer vaccine development. The stock is trading near the lower end of its 52‑week range, with RSI indicating modest momentum.
ATTO shares dip as investors question valuation after cancer vaccine news. Attovia Therapeutics' stock moved lower as investors raised concerns about whether its current valuation is justified. The scrutiny comes as the broader oncology space sees attention, highlighted by recent discussion of Moderna's cancer vaccine development. The stock is trading near the lower end of its 52‑week range, with RSI indicating modest momentum.